Sheet

PTO/SB/08a (01-08)

Approved for use through 06/30/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/652,864-Conf. #1487 INFORMATION DISCLOSURE August 29, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor Heinz Kohler Art Unit 1643 (Use as many sheets as necessary) A. Gussow Examiner Name IXS-10002/49 7 Attorney Docket Number of

		· ·							
	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Document Number Number-Kino Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	AA*	US-6,566,388	05-20-2003	Weber et al.					
	AB*	US-5,807,748	09-15-1998	Lin et al.					
	AC*	US-6,620,782	09-16-2003	Cai et al.					
	AD*	US-6,596,693	07-22-2003	Keana et al.					
	AE*	US-6,312,694	11-06-2001	Thorpe et al.					
	AF*	US-6,287,537	Q9-11-2001	Kaminski et al.					
	AG*	US-6,426,413	0 30-2002	Wannamaker et al.					
	AH*	US-6,228,603	05-88-2001	Reed et al.					
	Al*	US-6,821,274	11-23 2004	McHale et al.					
	AJ*	US-6,762,045	07-13-2804	Krebs et al.					
	AK*	US-6,432,680	08-13-200ିହ୍	Lin et al.					
	AL*	US-6,248,558	06-19-2001	Lin et al.					
	AM*	US-5,219,996	06-15-1993	Bodmer et al.					
	AN*	US-5,191,066	03-02-1993	Bienjarz et al.					
	AO*	US-6,218,160	04-17-2001	Dyan					
	AP*	US-6,716,410		Witzturk et al.					
	AQ*	US-6,780,605	08-24-2004	Frostegard et al.					
	AR*	US-20030143226	07-31-2003	Kobayashi et al.					
	AS*	US-20050033033	02-10-2005	Kohler et al.					

		FØREI	GN PATENT	DOCUMBNTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Gode ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T€
	ВА	WO-9620219	07-04-1996	Univ Kentucky et al.		
	ВВ	WO-9617625	06-13-1996	Lynxvale Ltd et al.		
	вс	WO-991424	03-25-1999	Kohler Heinz		
	Ĭ					
	<u> </u>					

Examiner Signature Date Considered

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the FW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a (01-08)

Approved for use through 06/30/2008, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/652,864-Conf. #1487 **INFORMATION DISCLOSURE** August 29, 2003 Filing Date STATEMENT BY APPLICANT Heinz Kohler First Named Inventor 1643 Art Unit (Use as many sheets as necessary) Examiner Name A. Gussow IXS-10002/49 7 Attorney Docket Number of Sheet

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code 2 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	AT*	US-5,276,1%0	01-04-1994	Kirk et al.				
	AU*	US-5,596,08 1	01-21-1997	Haley et al.				
	AV*	US-5,563,046 🔪	10-08-1996	Mascarenhas et al.				
	AW*	US-5,645,835	07-08-1997	Fell, Jr. et al.	,			
	AX*	US-5,698,679	12-16-1997	Nemazee				
	AY*	US-5,763,733	Q 6-09-1998	Whitlow et al.				
	AZ*	US-5,811,265	0\$ 22-1998	Quertermous et al.				
	AA1*	US-5,908,626	06-81-1999	Chang et al.				
	AB1*	US-5,969,109	10-19 1999	Bona et al.				
	AC1*	US-6,008,319	12-28-1399	Epstein et al				
	AD1*	US-6,117,656	09-12-2008	Seed				
	AE1*	US-5,668,255	09-16-1997	Murphy				
	AF1*	US-6,121,424	09-19-2000	Whitlow et al.				
	AG1*	US-6,132,992	10-17-2000	Ledwetter et al.				
	AH1*	US-6,207,804	03-27-2001	Hy≸ton et al.				
	Al1*	US-6,224,870	05-01-2001	Segal \				
	AJ1*	US-5,314,995	05-24-1994	Fell, Jr. et al.				
	AK1*	US-5,677,171	10-14-19\$7	Hudziak et al.				
	AL1*	US-6,043,339	03-28-2000	Lin et al.				

		FØREIG	GN PATENT D	OCUMBNTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind flode ⁵ (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶ .

Date Examiner Signature Considered

^{*}EXAMINER: Initian if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not conformance and not *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not reconsidered. The considered is the considered in the considered in the conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an sigle asteries (*) next to the Cite No are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the FW. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the imperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 06/30/2008, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/652,864-Conf. #1487 INFORMATION DISCLOSURE Filing Date August 29, 2003 STATEMENT BY APPLICANT First Named Inventor Heinz Kohler Art Unit 1643 (Use as many sheets as necessary) A. Gussow Examiner Name 7 IXS-10002/49 Attorney Docket Number Sheet of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the tem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	Binder, M., F. Otto, R. Mertelsmann, H. Veelken, and M. Trepel. "The epitope recognized by rituximab." Blook 2006, vol. 108, no. 6, pp.1975-1978.	
	СВ	Braendstrup, P., W. Bjerrum, O.J. Nielsen, B.A. Jensen, N.T. Clausen, P.B. Hansen, I. Andersen, K. Schmidt, T.M. Andersen, N.A. Peterslund, H.S. Birgens, T. Plesner, B.B. Pedersen, and H.C. Hasselbalch. "Rituximab Chimeric And-CD20 Monoclonal Antibody Treatment for Adult Refrectory Idiopathic Thrombocytopenic Purpura." American Journal of Hematology 2005, vol. 78, pp. 275-280.	
	СС	Burton, C., R. Kaczmarski, Jan-Mohamed. "Interstitial Pneumonitis Related to Rituximab Therapy." The New England Journal of Medicine 2003, vol. 348, no. 26, pp. 2690-2691.	
	CD	Edwards, J.C.W., L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, R.M. Stevens, and T. Shaw "Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis." The New England Journal of Medicine 2004, vol. 350, no. 25, pp. 2572-2581.	
	CE	Pandey, R.N., L.E. Davis, B. Anderson, and P.F. Hollenberg. "Photochemical linking of primary aromatic amines to carrier proteins to elicit antibody response against the amine haptens." Journal of Immunological Methods, 1986, vol. 94, pp. 237-246.	
	CF	Lambris, J.D., V.S. Ganu, S. Hirani, and H.J. Muller-Eberhard. "Mapping the C3d receptor (CR2)-binding site and a neophtigenic site in the C3d domain of the third component of complement." Proceedings of the National Academy of Sciences USA 1985, vol. 82, pp. 4235-4239.	
	CG	Frankel, A.E. "Antibody Toxin Hybrids: A Clinical Review of Their Use." Journal of Biological Response Modifiers 1985, vol. 4, pp. 437-446.	
	СН	Chaddock, J.A., L.M. Roberts, B. Jungnickel, and J. Michaell ord. "A hydrophobic region of ricin a chain which may have a role in membrane translocation can function as an efficient noncleaved signal peptide." Biochemical and Biophysical Research Communications 1995, vol. 217, no. , pp. 68-73.	
	СІ	Morris, K.N. and I.G. Wool. "Analysis of the contribution of an amphiphilic α-helix to the structure and to the function of ricin A chain." Proceedings of the National Academy of Science's USA 1994, vol. 91, pp. 7530-7533.	
	Cl	Kohler, H., G. Pavlinkova, K. Rajagopalan, H-T. Wang, S. Chatterjee, and S. Haley. "Specific photoaffinity-labeling locus on antibodies: use for chelation, protein conjungation and gene delivery." Journal of Cellular Biochemistry Supplement, Abstract T029, no. 18D, 1994, pp. 189.	

		6				
Examiner	A A		Date	· ·	M. T.	
Signature	A STATE OF THE STA		Considered		M.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

plicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (01-08)
Approved for use through 06/30/2008, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 10/652,864-Conf. #1487 Application Number INFORMATION DISCLOSURE Filing Date August 29, 2003 **STATEMENT BY APPLICANT** First Named Inventor Heinz Kohler 1643 Art Unit (Use as many sheets as necessary) A. Gussow Examiner Name 7 IXS-10002/49 of Attorney Docket Number Sheet

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials Cite No.! Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), t						
	ск	Pavlinkova, G. K. Rajagopalan, S. Muller, A. Chavan, G. Sievert, D. Lou, C. O'Toole, B. Haley, and H. Kahler. "Site-specific photobiotinylation of immunoglobulins, fragments and light chain dimers." Journal of Immunological Methods 1997, vol. 251, pp. 77-88.				
	CL	Miles, E.W. and R.S. Phillips. "Photoinactivation and Photos finity Labeling of Tryptophan Synthase α₂β₂ Complex by the Product Analogue 6-Azido L-tryptophan." Biochemistry 1985, vol. 24, pp. 4694-4703.				
	СМ	Rousselot, P., E. Mappus, T. Blachere, M. Rolland de Ravel, C. Grenot, C. Tonnelle, and C.Y. Cuilleron. "Specific Photoaffirity Labeling of Tyr-49 on the Light Chain in the Steroid-Combining Site of a Mouse Monoclonal Anti-Estradiol Antibody Using Two Epimeric 6α- and 6β-(5-Azido-2-nitrobenzoyl)amidoestradiol Photoreagents." Biochemistry 1997, vol. 36, pp. 7860-7868.				
	CN	Fleet, G.W.J., J.R. Knowles, and R.R. Porter. "The Antibody Binding Site: Labelling of a Specific Antibody Against the Photo-Precursor of an Aryl Nitrene." Biochemistry Journal 1972, vol. 128, pp. 499-508.				
	со	Lou, D. and H. Kohler. "Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide." Nature Biotechnology 1998, vol. 16, pp. 458-462.				
	СР	Demoliou, C.D. and R.M. Epand. "Synthesis and Characterization of a Heterobifunctional Photoaffinity Reagent for Modification of Tryptophan Residues and its Application to the Preparation of a Photoreactive Glucagon Derivative." Biochemistry 1980, vol. 19, pp. 4539-4546.				
	CQ	Foxwell, B.M.J., W.C.J. Ross, and P.E. Thorpe. "Antibody-Ricin Conjugates: A Method of Linkage which Blocks the Galactose Binding Site of Ricin. Behring Institute Mitteilungen 1984, no. 74, pp. 101-107				
	CR	Tao, M-H. and R Levy. "Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vascine for B-cell Lymphoma." Nature 1993, vol. 362, pp. 755-758.				
	cs	Johnston, A. G.R. Auda, M.A. Kerr, M.W. Steward, and K. Whaley "Dissociation of primary antigen-antibody bonds is essential for complement mediated solubilization of immune precipitates." Molecular Immunology 1992, vol. 29, no. 5, pp. 659-665.				
_	СТ	Thorpe, P.E. and W.C.J. Ross. "The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates." Immunological Review 1982, vol. 62 pp. 119-158.				

		8	 					
Examiner		A STATE OF THE STA	 <u>. </u>	 	Date	*	A.	
Signature	A	7 			Considered		M	

Mitial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not include copy of this form with next communication to applicant.

s unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (01-08)

Approved for use through 06/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/652,864-Conf. #1487 INFORMATION DISCLOSURE Filing Date August 29, 2003 **STATEMENT BY APPLICANT** First Named Inventor Heinz Kohler 1643 Art Unit (Use as many sheets as necessary) Examiner Name A. Gussow 7 IXS-10002/49 Sheet of Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of				
	CU	Zhao, Y., T.L. Brown, H. Kohler, and S. Muller. "MTS-conjugated-antiactive caspase 3 antibodies inhibit actinomycin D-induced apoptosis." Apoptosis 2003, vol. 8, pp. 631-637.				
	с٧	Hallbrink, M., A. Floren, A. Elmquist, M. Pooga, T. Bartfai, U. Langel. "Cargo delivery kinetics of cell-penetrating pertides." Biochimica et Biophysica Acta 2001, vol. 1515, pp. 101-109.				
Soomets, U., M. Lindgran, X. Gallet, M. Hallbrink, A. Elmquist, L. Balaspiri, M. Zorki CW Pooga, R. Brasseur, U. Langel. "Deletion analogues of transportan." Biochimica et Acta 2000, vol. 1467, pp. 165-176.						
	СХ	Fischer, P.M., N.Z. Zhelev, S. Wang, J.E. Melville, M. Fahraeus, D.P. Lane. "Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin." Journal of Peptide Research 2000 vol. 55, pp. 163-172.				
	CY	Lindberg, M., J. Jarvet, U. Langel, and A. Graslund. "Secondary Structure and Position of the Cell-Penetrating Peptide Transportan in SDS Micelles As Determined by NMR." Biochemistry 2001, vol. 40, pp. 3141-3149.				
	cz	Li, Y. R. V. Rosal, P.W. Brandt-Rauf, and R.L. Fine. "Correlation between hydrophobic properties and efficiency of carrier-mediated membrane transduction and apoptosis of a p53 C-terminal peptide." Biochemical and Biophysical Research Communications 2002, vol. 298, pp. 439-449.				
	CA1	Zanetti, M. "Antigenized antibodies." Nature 1992, vol. 355, pp. 476-477.				
	CB1	Zaghouani, H., S.A. Anderson, K.E. Sperber, C. Daiar, R.C. Kennedy, L. Mayer, and C.A. Bona. "Induction of antibodies to the human immunoded ciency virus type 1 by immunization of baboons with immunogobulin molecules carrying the principal neutralizing determinant of the envelope protein." Proceedings of the National Academy of Science USA 1995, vol. 92, pp. 631-635.				
	CC1	Kang, C., H. Cheng, S. Rudikoff, and H. Kohler. "Idiotypic self binding of a dominant germline idiotype (T15)." Journal of Experimental Medicine 1987, vol. 165, pp. 1332-1343.				
	CD1	Yan, X., S.V. Evans, M.J. Kaminki, S.D. Gillies, R.A. Reisfeld, A.N. Noughton, and P.B. Chapman. Characterization of an Ig V _H Idiotope That Results in Specific Homophilic Binding and Increased Avidity for Antigen." The Journal of Immunology 1996, vo. 157, pp. 1582-1588.				

Examiner Signature	Date Considered	
		16

^{*}EXAMINER: Initial inference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's upque citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached

PTO/SB/08b (01-08)

Approved for use through 06/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 10/652,864-Conf. #1487 **Application Number** INFORMATION DISCLOSURE Filing Date August 29, 2003 **STATEMENT BY APPLICANT** Heinz Kohler First Named Inventor Art Unit 1643 (Use as many sheets as necessary) A. Gussow Examiner Name 7 IXS-10002/49 Sheet Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the tem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CE1	Dempsey, P.W., M.E.D. Allison, S. Akkaraju, C.C. Goodnow, D.T. Fearon. "C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity." Science 1996, vol. 271, pp. 348-350.	
	CF1	Antoni, G., R. Presentini, F. Perin, A. Tagliabue, P. Ghiara, S. Censini, G. Volpini, L. Villa, and D. Boraschi. "A short with vithetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity." The Journal of Immunology 1986, vol. 137, pp. 3201-3204.	
	CG1	Bhattacharya-Chatterjee, M., S. Mukerjee, W. Biddle, K.A. Foon, and H. Kohler. "Murine monoclonal anti-idiotype antibody as a potential petwork antigen for human carcinoembryonic antigen." The Journal of Immunology 1990, vol 145, pp. 2758-2765.	
	CH1	Foon, K., M. Chakraborty, W.J. John, A. Sheratt, H. Kohler, and M. Bhattacharya-Chatterjee. "Immune Response to the Carcinoembryonic Antigen in Patients Treated with an Anti-Idiotype Antibody Vaccine." Journal of Clinical Institution 1995, vol. 96, pp. 334-342.	
	CI1	Kaminski, M.S., K. Kitamura, and D.G. Majoney, and R. Levy. "Idiotype Vaccination Against Murin B cell Lymphoma. Inhibition of Tumo Immunity by Free Idiotype Protein." The Journal of Immunology 1987, vol. 138, pp. 1289-1296.	
	CJ1	Abaza, M. and M.Z. Atassi. "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin." Journal of Protein Chemistry 1992, vol. 11, pp. 433-444.	
	CK1	Rojas, M. S. Yao, and Y.Z. Lin. "Controlling Epidermal Crowth Factor (EGF)-stimulated Ras Activation in Intact Colls by a Cell-permeable Peptide Minicking Phosphorylated EGF Receptor." The Joynal of Biological Chemistry 1996, vol. 274, no. 44.	
	CL1	Gerstmayer, B., V. Altenschmidt, M. Hoffman, and W. Wels. "Costimulation of T Cell Proliferation by a Chimeric B7-2 Antibody Fusion Protein Specifically Targeted to Cells Expressing the erbB2 Proto-Oncogene." Journal of Immunology 1997, vol. 158, pp. 4584-4590.	
	СМ1	Allison, K.C. "The Mode of Action of Immunological Adjuvants." Developments in Biological Standardization 1998, vol. 92, pp. 3-11.	

			<u> </u>	
Examiner	· · · · · · · · · · · · · · · · · · ·	Date	WARE TO SERVICE THE PERSON OF	
Signature		Considered	- NA	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not inconformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached

PTO/SB/08b (01-08)

Approved for use through 06/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/652,864-Conf. #1487 INFORMATION DISCLOSURE Filing Date August 29, 2003 STATEMENT BY APPLICANT First Named Inventor Heinz Kohler 1643 Art Unit (Use as many sheets as necessary) Examiner Name A. Gussow 7 IXS-10002/49 Sheet Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the tem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CN1	Awwad, M., P.G. Strome, S.C. Gilman, H.R. Axelrod. "Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimyci does not interfere with antibody effector functions." Cancer Immunology Immunother by 1994, vol. 38, pp. 23-30.	
	CO1	Binder, C.J., S. Horkto, A. Dewan, M. Chang, E.P. Kieu, C.J. Goodyear, P.X. Shaw, W. Palinski, J.L. Witztum, and G.J. Silverman. "Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL." Nature Medicine 2003, vol. 9, pp. 736, 43.	
			<u> </u>
			┡
		V	┞
		<u> </u>	ļ
			L
F	1	10-11	
Examine	` 	Date	

^{*}EXAMINER: Initial if reference considered, whether or pot citation is in conformance with MPEP 6.9. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Signature

^{&#}x27;Applicant's unique citation designation number (gritonal). 2Applicant is to place a check mark here it English language Translation is attached.